Innovation, Research
Ribonexus: Overcoming resistance to cancer treatments
… they developed their research via the creation, in July 2021, of a start-up, thanks to incubator programmes and … Aglaia Therapeutics, it was renamed Ribonexus in November 2021. In February 2022, it received €1.5 million in funding … after a licence agreement was signed in November 2021 for co-development purposes. “With the Ribonexus team, …
Published on: